Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep 30:13:944387.
doi: 10.3389/fimmu.2022.944387. eCollection 2022.

Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis

Liuting Zeng  1 , Ying Deng  1 , Kailin Yang  2 , Junpeng Chen  3 , Qi He  4 , Hua Chen  1
Affiliations
Meta-Analysis

Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis

Liuting Zeng et al. Front Immunol. .

Abstract

Objective: To evaluate the safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases.

Methods: Relevant literature was retrieved from the PubMed database, Embase database, Cochrane Library database, etc. The search period is from the establishment of the database to January 2022. The outcomes include clinical symptoms, improvement in biochemistry, improvement in intestinal microbiota, improvement in the immune system, and adverse events. Literature screening and data extraction were independently carried out by two researchers according to the inclusion and exclusion criteria, and RevMan 5.3 software was used for statistics and analysis.

Results: Overall, a total of 14 randomized controlled trials (RCTs) involving six types of autoimmune diseases were included. The results showed the following. 1) Type 1 diabetes mellitus (T1DM): compared with the autologous fecal microbiota transplantation (FMT) group (control group), the fasting plasma C peptide in the allogenic FMT group at 12 months was lower. 2) Systemic sclerosis: at week 4, compared with one of two placebo controls, three patients in the experimental group reported a major improvement in fecal incontinence. 3) Ulcerative colitis, pediatric ulcerative colitis, and Crohn's disease: FMT may increase clinical remission, clinical response, and endoscopic remission for patients with ulcerative colitis and increase clinical remission for patients with Crohn's disease. 4) Psoriatic arthritis: there was no difference in the ratio of ACR20 between the two groups.

Conclusion: Based on current evidence, the application of FMT in the treatment of autoimmune diseases is effective and relatively safe, and it is expected to be used as a method to induce remission of active autoimmune diseases.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021235055, identifier CRD42021235055.

Keywords: autoimmune diseases; autoinflammatory diseases; fecal microbiota transplantation; meta-analysis; systemic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Risk of bias assessment. (A) Risk of bias graph. (B) Risk of bias summary.
Figure 3
Figure 3
Clinical remission.
Figure 4
Figure 4
Clinical response.
Figure 5
Figure 5
Endoscopic remission.
Figure 6
Figure 6
Endoscopic response.
Figure 7
Figure 7
Adverse events.
Figure 8
Figure 8
Severe adverse events.
Figure 9
Figure 9
Clinical remission.
Figure 10
Figure 10
The intervention mechanism of fecal microbiota transplantation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med (2015) 278(4):369–95. doi: 10.1111/joim.12395 - DOI - PubMed
    1. Rose NR. Prediction and prevention of autoimmune disease in the 21st century: A review and preview. Am J Epidemiol (2016) 183(5):403–6. doi: 10.1093/aje/kwv292 - DOI - PubMed
    1. Xu F, Jin L, Jin Y, Nie Z, Zheng H. Long noncoding RNAs in autoimmune diseases. J BioMed Mater Res A (2019) 107(2):468–75. doi: 10.1002/jbm.a.36562 - DOI - PubMed
    1. Quinn MJ. Organ-specific “autoimmune” disease. J Clin Gastroenterol (2009) 43(4):386–7. doi: 10.1097/MCG.0b013e318173e10e - DOI - PubMed
    1. Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun (2020) 109:102421. doi: 10.1016/j.jaut.2020.102421 - DOI - PMC - PubMed

MeSH terms